Insulet (NASDAQ:PODD) Reaches New 1-Year Low – What’s Next?

Insulet Corporation (NASDAQ:PODD)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $205.11 and last traded at $208.01, with a volume of 792667 shares changing hands. The stock had previously closed at $208.22.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $380.00 price target on shares of Insulet in a research note on Wednesday, February 18th. JPMorgan Chase & Co. reduced their price objective on Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research report on Thursday, February 19th. Barclays restated an “underweight” rating and issued a $286.00 target price on shares of Insulet in a research note on Thursday, February 19th. Truist Financial cut their price target on Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Finally, Sanford C. Bernstein reduced their price target on Insulet from $380.00 to $330.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $354.24.

Insulet Stock Down 0.1%

The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The business’s fifty day moving average price is $244.14 and its two-hundred day moving average price is $287.40. The firm has a market cap of $14.64 billion, a P/E ratio of 59.43, a P/E/G ratio of 1.25 and a beta of 1.42.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The firm had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. Insulet’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.15 earnings per share. As a group, equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Activity

In related news, Director Michael R. Minogue purchased 2,030 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC boosted its position in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the fourth quarter worth $28,000. DV Equities LLC acquired a new stake in shares of Insulet in the fourth quarter worth $28,000. Finally, MV Capital Management Inc. bought a new stake in shares of Insulet during the 4th quarter worth $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.